Article

EU GMP Updates 2026: What Irish Life Sciences Teams Need to Know

  • From: Roisin McNamara
  • Published on:
  • Last updated on:

Good Manufacturing Practice is continuously updated as manufacturing technology, data systems, supply chains and regulatory risks evolve. However, pharmaceutical organisations need to distinguish between current requirements, published revisions and consultation drafts. 

As of 30 July 2026, the proposed revisions to EU GMP Chapter 4 and Annex 11 and the proposed new Annex 22 on artificial intelligence have not been published as final EU GMP requirements. The consultation closed on 7 October 2025, but the official EudraLex Volume 4 page continues to list the January 2011 versions of Chapter 4 and Annex 11 and does not list Annex 22 as a final annex.

EU GMP updates for Irish pharmaceutical and life-sciences teams in 2026

Irish pharmaceutical and biopharmaceutical employers should still study the drafts and prepare for their likely direction. They should not, however, describe draft wording as legally operative or give teams an unconfirmed implementation date.

What Is the Current Status of the EU GMP Updates?

GMP document Status on 30 July 2026
Chapter 4: Documentation Proposed revision; consultation closed
Annex 11: Computerised Systems Proposed revision; consultation closed
Annex 22: Artificial Intelligence Proposed new annex; consultation closed
Annex 19: Reference and Retention Samples Final revision published; applicable 24 September 2026
Annex 1: Sterile Medicinal Products Fully applicable since 25 August 2024

 

The European Commission consulted stakeholders on Chapter 4, Annex 11 and Annex 22 between July and October 2025. The drafts were developed to address electronic documentation, modern computerised systems and the use of AI and machine learning in pharmaceutical manufacturing.

The article should not predict that these documents will take effect during 2026 or 2027 unless the European Commission publishes a final version and confirmed implementation date.

Draft Chapter 4: Documentation

A major workstream underway across the EU regulatory landscape is the revision of three core elements of the EU GMP Guidelines: 

  • Annex 11: Computerised Systemshas expanded to include modern digital platforms, cloud computing, third‑party software, and CI/CD practices.
  • Chapter 4: Documentation, updated to reflect the need for robust, electronic, and hybrid records management.
  • Annex 22: Artificial Intelligence (AI), a newly drafted annex focused on GMP use of AI tools.  

Draft versions were published for public consultation until October 2025, with final publication expected in mid‑2026 and likely implementation over 2026-2027.  

What teams should do now

Teams that rely on legacy paper systems or siloed software must urgently shift to modern, validated environments. We’re seeing a demand from hiring managers for candidates with experience in computerised system validation (CSV), risk‑based digital compliance, and documentation automation. 

Quality Risk Management Is Being Reframed 

ICH Q9 (Quality Risk Management) principles are now central to how GMP revisions are being interpreted globally. Modern risk management emphasises decision science and evidence‑led approaches, not just checklists.  

Expectation shift for teams: 

  • Risk management must be proactive and embedded in daily operations
  • AI and automation tools may be used to generate risk scenarios, but human oversight remains essential
  • Documentation of decision quality (not just outcomes) will be scrutinised in audits 

Hiring managers are workforce planning for quality professionals with robust risk competency and decision science experience to meet higher demand, particularly those who can integrate risk frameworks with operational workflows. 

Check out: Quality Jobs in Ireland

Distribution Compliance (GDP) Is Also Tightening 

While not strictly GMP, updated Good Distribution Practice (GDP) guidance  has implications for quality and supply chain teams. Sections on supplier approval, product verification, and decommissioning identifiers have all been expanded.  

Takeaway: 

Whether you work in quality assurance, supply chain, or wholesale/distribution operations, organisations are now hiring with a sharper eye on GDP experience and compliance culture. 

If you're considering contracting, check out: Quality Contracting Rate Guide Ireland 2026

What This Means for Candidates 

If you’re aiming for roles in quality, validation, regulatory affairs, or manufacturing oversight in Ireland: 

  • Digital systems experience is now essential. Modern GMP compliance relies heavily on validated software and automated documentation.
  • Risk management competency goes beyond theory. Employers want professionals who can demonstrate decisions made using risk science.
  • Sector‑specific GMP knowledge is rare and valuable. Radio pharma, APIs, sterile manufacturing, and distribution controls are all evolving, and expertise in these areas will command premium opportunities. 

What This Means for Hiring Managers 

From a workforce planning perspective: 

  • Audit preparedness is a hiring driver. The expanding digital and documentation requirements push organisations to hire or upskill for CSV, PQS integration, and digital compliance expertise.
  • Contract talent may bridge skill gaps. Specialist compliance rolesparticularly around Annex 11, documentation systems, and radio pharma GMPmay best be fulfilled initially with experienced contract professionals.
  • Training and internal development matters. Given ongoing revisions, internal quality teams must be supported with training on evolving GMP standards. 

Plan your next hire check out: Permanent Salary Guide Ireland 2026 and Contracting Rate Guide Ireland 2026

If your team needs GMP‑ready compliance expertisewhether for immediate audit cycles, documentation transformation, or advanced quality systems connect with our specialists: hello@hero.ie o (01) 619 0279. 

 
Common questions

FAQs

FAQs

The confirmed human-medicines update is the revised Annex 19 on reference and retention samples, which becomes applicable on 24 September 2026. Revised Chapter 4, revised Annex 11 and new Annex 22 remain consultation drafts as of 30 July 2026.

No. The official EudraLex Volume 4 page still lists the January 2011 Annex 11. The proposed replacement completed consultation in October 2025 but has not yet been listed as the final applicable version.

Annex 22 has been published as a consultation draft, not as a final applicable EU GMP annex. Organisations can use it to understand likely regulatory direction but should not describe themselves as formally compliant with a final Annex 22.

No confirmed final publication or implementation date should be stated until the European Commission publishes the completed documents. The consultation ended on 7 October 2025, but consultation closure does not itself make the drafts effective.

The revised Annex 19 updates requirements for reference and retention samples, with particular clarification for parallel-imported, distributed or traded products. It also permits photographic or digital retention samples in limited, justified circumstances agreed with the competent authority.

Companies should review system inventories, validation, data integrity, supplier oversight, audit trails, access control, backup and recovery, periodic review and system retirement. They should use the draft to anticipate likely direction while continuing to comply with the currently applicable Annex 11.

The draft would require organisations to define intended use, control training and test data, establish acceptance criteria, validate model performance, monitor changes and provide human review where necessary. These provisions remain proposed rather than final.

GMP covers the manufacture and testing of medicinal products and active substances. GDP governs the controlled wholesale distribution, storage and transport of medicinal products after manufacture. Some quality and supply-chain roles require knowledge of both frameworks.

EU GMP primarily applies to medicinal products, active substances and clinical-trial medicines. Medical devices and IVDs are regulated through separate medical-device frameworks, including the MDR and IVDR, although some organisations and combination products may be subject to overlapping requirements.

Relevant skills include quality assurance, computerised-system validation, data integrity, quality risk management, validation, sterile manufacturing, contamination control, audit preparation, CAPA, supplier oversight and regulated digital-system governance.

Search Jobs

Match my CV

We take the hard work out of finding you a new job. Simply upload your CV (or call us) and we’ll get hunting for you!

Subscribe to The Shift for the latest STEM industry and career updates.

placeholders
Join The Shift!

Get insider updates on the hottest industry trends, cutting-edge career advice, and exclusive talent insights. Stay ahead of the curve and keep your finger on the pulse of Ireland’s STEM talent trends. Exciting content coming your way soon!